×
S&P 500   3,823.03 (-0.22%)
DOW   30,939.00 (-0.09%)
QQQ   287.29 (+0.11%)
AAPL   141.72 (+0.11%)
MSFT   263.05 (+0.08%)
META   166.85 (-0.80%)
GOOGL   2,260.46 (-0.21%)
AMZN   113.41 (-0.08%)
TSLA   698.77 (-0.06%)
NVDA   150.27 (+0.42%)
NIO   21.18 (-4.51%)
BABA   116.96 (-2.64%)
AMD   74.98 (-0.29%)
MU   57.37 (+1.13%)
CGC   2.70 (-0.37%)
T   21.16 (-0.05%)
F   11.03 (-1.52%)
DIS   97.13 (-0.05%)
AMC   12.69 (-0.70%)
PFE   52.09 (+0.87%)
PYPL   74.35 (-0.07%)
NFLX   184.52 (-0.73%)
S&P 500   3,823.03 (-0.22%)
DOW   30,939.00 (-0.09%)
QQQ   287.29 (+0.11%)
AAPL   141.72 (+0.11%)
MSFT   263.05 (+0.08%)
META   166.85 (-0.80%)
GOOGL   2,260.46 (-0.21%)
AMZN   113.41 (-0.08%)
TSLA   698.77 (-0.06%)
NVDA   150.27 (+0.42%)
NIO   21.18 (-4.51%)
BABA   116.96 (-2.64%)
AMD   74.98 (-0.29%)
MU   57.37 (+1.13%)
CGC   2.70 (-0.37%)
T   21.16 (-0.05%)
F   11.03 (-1.52%)
DIS   97.13 (-0.05%)
AMC   12.69 (-0.70%)
PFE   52.09 (+0.87%)
PYPL   74.35 (-0.07%)
NFLX   184.52 (-0.73%)
S&P 500   3,823.03 (-0.22%)
DOW   30,939.00 (-0.09%)
QQQ   287.29 (+0.11%)
AAPL   141.72 (+0.11%)
MSFT   263.05 (+0.08%)
META   166.85 (-0.80%)
GOOGL   2,260.46 (-0.21%)
AMZN   113.41 (-0.08%)
TSLA   698.77 (-0.06%)
NVDA   150.27 (+0.42%)
NIO   21.18 (-4.51%)
BABA   116.96 (-2.64%)
AMD   74.98 (-0.29%)
MU   57.37 (+1.13%)
CGC   2.70 (-0.37%)
T   21.16 (-0.05%)
F   11.03 (-1.52%)
DIS   97.13 (-0.05%)
AMC   12.69 (-0.70%)
PFE   52.09 (+0.87%)
PYPL   74.35 (-0.07%)
NFLX   184.52 (-0.73%)
S&P 500   3,823.03 (-0.22%)
DOW   30,939.00 (-0.09%)
QQQ   287.29 (+0.11%)
AAPL   141.72 (+0.11%)
MSFT   263.05 (+0.08%)
META   166.85 (-0.80%)
GOOGL   2,260.46 (-0.21%)
AMZN   113.41 (-0.08%)
TSLA   698.77 (-0.06%)
NVDA   150.27 (+0.42%)
NIO   21.18 (-4.51%)
BABA   116.96 (-2.64%)
AMD   74.98 (-0.29%)
MU   57.37 (+1.13%)
CGC   2.70 (-0.37%)
T   21.16 (-0.05%)
F   11.03 (-1.52%)
DIS   97.13 (-0.05%)
AMC   12.69 (-0.70%)
PFE   52.09 (+0.87%)
PYPL   74.35 (-0.07%)
NFLX   184.52 (-0.73%)
NASDAQ:AKBA

Akebia Therapeutics Stock Forecast, Price & News

$0.40
-0.01 (-2.41%)
(As of 07/6/2022 09:35 AM ET)
Add
Compare
Today's Range
$0.39
$0.40
50-Day Range
$0.32
$0.45
52-Week Range
$0.30
$3.71
Volume
5,145 shs
Average Volume
17.31 million shs
Market Capitalization
$73.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.75

Akebia Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
327.9% Upside
$1.75 Price Target
Short Interest
Healthy
8.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.75
Upright™ Environmental Score
News Sentiment
0.50mentions of Akebia Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$1,644 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.88) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.15 out of 5 stars

Medical Sector

326th out of 1,426 stocks

Pharmaceutical Preparations Industry

153rd out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Akebia Therapeutics logo

About Akebia Therapeutics (NASDAQ:AKBA) Stock

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AKBA Stock News Headlines

Akebia falls as agreement with Otsuka Pharma ends
Expert Ratings for Akebia Therapeutics
Following FDA rejection, Akebia lays off 180 workers
Akebia stock tumbles after FDA rejects anemia drug
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKBA
Employees
426
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/06/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$1.75
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$1.25
Forecasted Upside/Downside
+337.4%
Consensus Rating
Hold
Rating Score (0-4)
2
Research Coverage
6 Analysts

Profitability

Net Income
$-282,840,000.00
Net Margins
-123.64%
Pretax Margin
-123.64%

Debt

Sales & Book Value

Annual Sales
$213.58 million
Book Value
$0.44 per share

Miscellaneous

Free Float
178,174,000
Market Cap
$73.43 million
Optionable
Optionable
Beta
1.49














Akebia Therapeutics Frequently Asked Questions

Should I buy or sell Akebia Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Akebia Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKBA, but not buy additional shares or sell existing shares.
View analyst ratings for Akebia Therapeutics
or view top-rated stocks.

What is Akebia Therapeutics' stock price forecast for 2022?

6 analysts have issued 12-month price targets for Akebia Therapeutics' shares. Their AKBA stock forecasts range from $1.25 to $2.00. On average, they predict Akebia Therapeutics' stock price to reach $1.75 in the next year. This suggests a possible upside of 337.4% from the stock's current price.
View analysts' price targets for Akebia Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Akebia Therapeutics' stock performed in 2022?

Akebia Therapeutics' stock was trading at $2.26 at the beginning of the year. Since then, AKBA stock has decreased by 82.3% and is now trading at $0.4001.
View the best growth stocks for 2022 here
.

When is Akebia Therapeutics' next earnings date?

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Akebia Therapeutics
.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.08. The biopharmaceutical company had revenue of $61.70 million for the quarter, compared to analyst estimates of $44.37 million. Akebia Therapeutics had a negative net margin of 123.64% and a negative trailing twelve-month return on equity of 266.13%. During the same quarter in the previous year, the company earned ($0.45) earnings per share.
View Akebia Therapeutics' earnings history
.

Who are Akebia Therapeutics' key executives?

Akebia Therapeutics' management team includes the following people:

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics CEO John Butler on Glassdoor.com. John Butler has an approval rating of 97% among Akebia Therapeutics' employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How do I buy shares of Akebia Therapeutics?

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akebia Therapeutics' stock price today?

One share of AKBA stock can currently be purchased for approximately $0.40.

How much money does Akebia Therapeutics make?

Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $73.43 million and generates $213.58 million in revenue each year. The biopharmaceutical company earns $-282,840,000.00 in net income (profit) each year or ($1.60) on an earnings per share basis.

How many employees does Akebia Therapeutics have?

Akebia Therapeutics employs 426 workers across the globe.

How can I contact Akebia Therapeutics?

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for Akebia Therapeutics is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099.

This page (NASDAQ:AKBA) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.